Trichostatin A suppresses transformation by the v-myb oncogene in BM2 cells

Journal of Hematotherapy and Stem Cell Research

Volumn 12, Issue 2, 2003, Pages 225-235

  Nemajerová, Alice ^a,b   Šmarda, Jan ^b   Jurdic, Pierre ^c   Kubala, Lukáš ^d   Souček, Karel ^d   Šmardova, Jana ^a  

^a MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

^b MASARYK UNIVERSITY   (Czech Republic)

^c UNIVERSITÉ DE LYON   (France)

^d INSTITUTE OF BIOPHYSICS   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE DEACETYLASE; PHORBOL ESTER; TRICHOSTATIN A;

ACETYLATION; ANIMAL CELL; ARTICLE; CELL CYCLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL TRANSFORMATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME INHIBITION; GENE OVEREXPRESSION; HEMATOPOIESIS; INHIBITION KINETICS; LEUKEMIA CELL; MACROPHAGE; NONHUMAN; ONCOGENE MYB; ONCOGENE V MYB; PHAGOCYTOSIS; PRIORITY JOURNAL; REGULATORY MECHANISM; RESPIRATORY BURST; TRANSCRIPTION REGULATION;

ACETYLATION; ANIMALS; CELL CYCLE; CELL DIFFERENTIATION; CELL LINE, TRANSFORMED; CELL TRANSFORMATION, VIRAL; CHICKENS; CHROMATIN ASSEMBLY AND DISASSEMBLY; GENES, MYB; HISTONE DEACETYLASES; HISTONES; HYDROXAMIC ACIDS; MACROPHAGES;

EID: 0038414978     PISSN: 15258165     EISSN: None     Source Type: Journal    
DOI: 10.1089/152581603321628368     Document Type: Article

References (47)

1. Shivdasani RA and SH Orkin. (1996). The transcriptional control of hematopoiesis. Blood 87:4025-4039.
2. Akahashi K, D Traver, T Miyamoto and IL Weissman. (2000). A clonogenic common myeloid progenitor that gives rise to all myeloid lineages. Nature 404:193-197.
3. Sterner DE and SL Berger. (2000). Acetylation of histones and transcription-related factors. Microbiol Mol Biol Rev 64:435-459.
4. Redner RL, J Wang and JM Liu. (1999). Chromatin remodeling and leukemia: New therapeutic paradigms. Blood 94:417-428.
5. Kijima M, M Yoshida, K Sugita, S Horinouchi and T Beppa. (1993). Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase. J Biol Chem 268:22429-22435.
6. Nakajima H, YB Kim, H Terano, M Yoshida and S Horinouchi. (1998). FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. Exp Cell Res 241:126-133.
7. Kim YB, KH Lee, K Sugita, M Yoshida and S Horinouchi. (1999). Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase. Oncogene 18:2461-2470.
8. Boffa LC, G Vidali, RS Mann and VG Allfrey. (1978). Suppression of histone deacetylation in vivo and in vitro by sodium butyrate. J Biol Chem 253:3364-3366.
9. Richon VM, Y Webb, R Merger, T Sheppard, B Jursic, L Ngo, F Civoli, R Breslow, RA Rifkind and PA Marks. (1996). Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Proc Natl Acad Sci USA 93:5705-5708.
10. Yoshida M, S Nomura and T Beppu. (1987). Effects of trichostatin on differentiation of murine erythroleukemia cells. Cancer Res. 47:3688-3691.
11. Yoshida M, M Kijima, M Akita and T Beppu. (1990). Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin. J Biol Chem 265:17174-17179.
12. Van Lint C, S Emiliani and E Verdin. (1996). The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gene Expr 5:245-253.
13. Marks PA, VM Richon, R Breslow and RA Rifking. (2001). Histone deacetylase inhibitors as new cancer drugs. Curr Opin Oncol 13:477-483.
14. Minucci S, C Nervi, F Lo Coco and PG Pelicci. (2001). Histone deacetylases: a common molecular target for differentiation treatment of acute myeloid leukemias? Oncogene 20:3110-3115.
15. Pandolfi PP. (2001). Transcription therapy for cancer. Oncogene 20:3116-3127.
16. Moscovici C, N Zeller and MG Moscovici. (1981). Continuous lines of AMV-transformed nonproducer cells: Growth and oncogenic potential in the chick embryo. In: Expression of Differentiated Function in Cancer Cells. RF Revoltella, C Basilico, RC Gallo, GM Pontieri, G Rovera and JH Subak-Sharpe, eds. Raven Press, New York, pp 325-449.
17. Beug H, PA Blundell and T Graf. (1987). Reversibility of differentiation and proliferative capacity in avian myelomonocytic cells transformed by tsE26 leukemia virus. Genes Dev 1:277-286.
18. Pessano S, L Gazzolo and M Moscovici. (1979). The effect of a tumor promoter on avian leukemic cells. Microbiologica 2:379-392.
19. Symonds G, KH Klempnauer, GI Evan and JM Bishop. (1984). Induced differentiation of avian myeloblastosis virus-transformed myeloblasts: Phenotypic alteration without altered expression of the viral oncogene. Mol Cell Biol 4:2587-2593.
20. Smarda J, J Sugarman, C Glass and J Lipsick. (1995). Retinoic acid receptor a suppresses transformation by v-myb. Mol Cell Biol 15:2474-2481.
21. Smarda J, K Zemanova, J Bryja, J Smardova, A Kozubik, J Hofmanova, A Nemajerova, S Sevcikova, J Kohoutek and P Vodicka. (1999). Retinoid X receptor suppresses transformation by v-myb oncogene. J Leuk Biol 66:1039-1048.
22. Waseem NH and DP Lane. (1990). Monoclonal antibody analysis of the proliferating cell nuclear antigen (PCNA). Structural conservation and the detection of a nucleolar form. J Cell Sci 96:121-129.
23. Bonner WM, MHP West and JD Stedman. (1980). Two-dimensional gel analysis of histones in acid-extracts of nuclei and tissues. Eur J Biochem 109:17-23.
24. Vindelov LL. (1977). Flow microfluorometric analysis of nuclear DNA in cells from solid tumors and cell suspensions. A new method for rapid isolation and staining of nuclei. Virchow's Arch B Cell Pathol 24:227-242.
25. Lojek A, M Ciz, P Marnila, M Duskova and EM Lilius. (1997). Measurement of whole blood phagocyte chemiluminescence in the Wistar rat. J Biolumin Chemilumin 12:255-231.
26. Fu SL and JS Lipsick. (1996). FAETL motif required for leukemic transformation by v-Myb. J Virol 70:5600-5610.
27. Vodička P, S Ševčiková, J Šmardová, K Souček and J Šmarda. (2000). The effects of RARα and RXRα proteins on growth, viability, and differentiation of v-myb-transformed monoblasts. Blood Cells Mol Dis 26:395-406.
28. Ausubel FM, R Brent, RE Kingston, DD Moore, JG Seidman, JA Smith and K Struhl. (1989). In: Current Protocols in Molecular Biology, John Wiley & Sons, New York, pp 9.7.12-9.7.14.
29. Sambrook J, EF Fritsch and T Maniatis. (1989). Molecular Cloning: A Laboratory Manual, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
30. de Wet J, KV Wood, M DeLucas, DR Helsinki and S Subramani. (1987). Firefly luciferase gene: structure and expression in mammalian cells. Mol Cell Biol 7:725-737.
31. 3 regulates the expression of carbonic anhydrase II in nonerythroid avian bone marrow cells. Proc Natl Acad Sci USA 87:6470-6474.
32. Solari F, F Flamant, Y Cherel, M Wyers and P Jurdic. (1996). The osteoclast generation: an in vitro and in vivo study with a genetically labelled avian monocytic cell line. J Cell Sci 109:1203-1213.
33. Teitelbaum SL. (2000). Bone resorption of osteoclasts. Science 289:1504-1508.
34. Coradini D, C Pellizzaro, D Marimpietri, G Abolafio and MG Daidone. (2000). Sodium butyrate modulates cell cycle-related proteins in HT29 human colonic adenocarcinoma cells. Cell Prolif 33:139-146.
35. Ganter B, SL Fu and JS Lipsick. (1998). D-type cyclins repress transcriptional activation by the v-Myb but not the c-Myb DNA-binding domain. EMBO J 17:255-268.
36. Grunstein M. (1997). Histone acetylation in chromatin structure and transcription. Nature 389:349-352.
37. Hoshikawa Y, HJ Kwon, M Yoshida, S Horinouchi and T Beppu. (1994). Trichostatin A induces morphological changes and gelsolin expression by inhibiting histone deacetylase in human carcinoma cell lines. Exp Cell Res 214:189-197.
38. Futamura M, Y Monden, T Okabe, J Fujita-Yoshigaki, S Yokoyama and S Nishimura. (1995). Trichostatin A inhibits both ras-induced neurite outgrowth of PC12 cells and morphological transformation of NIH3T3 cells. Oncogene 10:1119-1123.
39. McBain JA, A Eastman, CS Nobel and GC Mueller. (1997). Apoptotic death in adenocarcinoma cell lines induced by butyrate and other histone deacetylase inhibitors. Biochem Pharmacol 53:1357-1368.
40. Yoshida M and T Beppu. (1988). Reversible arrest of proliferation of rat 3Y1 fibroblasts in both the G1 and G2 phases by trichostatin A. Exp Cell Res 177:122-131.
41. Dini PW, JT Eltman and JS Lipsick. (1995). Mutations in the DNA-binding and transcriptional activation domains of v-Myb cooperate in transformation. J Virol 69:2515-2524.
42. Chen RH, S Fields and JS Lipsick. (1995). Dissociation of transcriptional activation and oncogenic transformation by v-Myb. Oncogene 11:1771-1779.
43. Burk O, S Mink, M Ringwald and KH Klempnauer. (1993). Synergistic activation of the chicken mim-1 gene by v-Myb and C/EBP transcription factors. EMBO J 12:2027-2038.
44. Ness SA, E Kowenz-Leutz, T Casini, T Graf and A Leutz. (1993). Myb and NF-M: Combinatorial activators of myeloid genes in heterologous cell types. Genes Dev. 7:749-753.
45. Boissy P, O Destaing and P Jurdic. (2001). RANKL induces formation of avian osteoclasts from macrophages but not from macrophage polykaryons. Biochem Biophys Res Commun 288:340-346.
46. Breitman TR, TE Selonick and SJ Collins. (1980). Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid. Proc Natl Acad Sci USA 77:2936-2940.
47. Engelke U, DM Wang and JS Lipsick. (1997). Cells transformed by a v-Myb-estrogen receptor fusion differentiate into multinucleated giant cells. J Virol 71:3760-3766.